IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Grutzmann, et al.

Serial No.: National Stage Filing of PCT/EP00/05410

Filed: DEC 2 1 2001

For: Combination of MTP Inhibitors and HMG-CoA Reductase Inhibitors and the Use Thereof in

Medicaments

BOX PCT ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: 20 Dec 101

William F. Gray

Attorney for Applicant(s)

Bayer Corporation

400 Morgan Lane

West Haven, CT 06516